Last reviewed · How we verify

NCT00383344

Use of FDG PET/CT to Evaluate Crohn Disease

Completed Phase 2 Last updated 9 December 2024
What this trial tests

Phase 2 trial testing FDG PET/CT in Crohn Disease in 30 participants. Completed in 1 May 2007.

Timeline
1 October 2006
Primary endpoint
1 May 2007
1 May 2007

Quick facts

Lead sponsorEric Turcotte
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment30
Start date1 October 2006
Primary completion1 May 2007
Estimated completion1 May 2007
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Eric Turcotte

Who can join

18 and older, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study will permit to determine the role of FDG PET/CT to diagnose Crohn Disease and recurrence of Crohn disease after having compared results of PET/CT's with results of exams routinely performed(colonoscopy and bowel follow through).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of FDG PET/CT

Trials testing the same drug.

Other recruiting trials for Crohn Disease

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00383344.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing